Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 107
News
News | 22 December 2022

Lupin Diagnostics expands footprint in Central India

The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price

News
News | 22 December 2022

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

News
News | 22 December 2022

Vaishali Pharma signs partnership agreement with Jark Pharma

As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products

News
News | 22 December 2022

Torrent board approves Scheme of Amalgamation of Curatio Health Care

The scheme is subject to statutory and regulatory approvals as may be necessary.

News
News | 21 December 2022

Indira IVF forays into diagnostic business with ‘Indira Pathlabs’

Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients

News
News | 20 December 2022

Ipca acquires further 6.53% of equity share of Trophic Wellness

Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.

News
News | 20 December 2022

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai

News
News | 20 December 2022

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

News
News | 19 December 2022

SRL Diagnostics launches laboratory in Panchkula

The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology

News
News | 19 December 2022

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies

News
News | 19 December 2022

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients

News
News | 19 December 2022

Stake sale in GMM Pfaudler by Pfaudler

Post the sale, Patel family has become the single largest promoter shareholder in the company

News
News | 19 December 2022

Mandaviya inaugurates ICMR-NARFBR in Hyderabad

The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.

News
News | 16 December 2022

Synchron raises $75 mn Series C Led by ARCH Venture Partners

Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors

News
News | 15 December 2022

China aims to lead next bio revolution in advanced biologics, says GlobalData

China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production

News
News | 15 December 2022

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.

News
News | 15 December 2022

ELIX Polymers and Ayudame3D to produce prostheses using recovered ABS

Ayúdame3D has become a leading social entity in social technology.

News
News | 15 December 2022

Torrent enters into co-marketing partnership with Boehringer Ingelheim India

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.

Startup

Digitization